Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy

Zhao, He; Xu, Jun; Li, Yan; Guan, Xinxian; Han, Xiao; Xu, Yunyun; Zhou, Huiting; Peng, Rui; Wang, Jian; Liu, Zhuang

doi:10.1021/acsnano.9b05974

Cited by 96 publications

(68 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is highly desirable to improve the immune response rate and selectively destroy primary solid tumors and metastatic lesions. In recent years, immunotherapy combined with nanotechnology, defined as nanoimmunotherapy, has shown promising performance for cancer therapy [ [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] ]. Among these therapeutics, metal-organic frameworks (MOFs), as a crystal material, has been widely studied in biomedical field [ [31] , [32] , [33] , [34] , [35] , [36] , [37] ].…”

Section: Introductionsmentioning

confidence: 99%

Reversing cold tumors to hot: An immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy

Fan

Liu

Xue

et al. 2021

Bioactive Materials

135

View full text Add to dashboard Cite

Immunotherapy assays using immunoadjuvants and tumor antigens could greatly increase the survival rates of patients with malignant tumors. As effective carriers, metal-organic frameworks (MOFs) have been widely utilized in cancer therapy due to their remarkable histocompatibility and low toxicity. Herein, we constructed a multimodal imaging-guided synergistic cancer photoimmunotherapy by employing a specific MOF (MIL101-NH 2 ) as the core carrier; the MOF was dual-dressed with photoacoustic and fluorescent signal donors (indocyanine green, ICG) and immune adjuvants (cytosine-phosphate-guanine sequence, CpG) and named ICG-CpG@MOF. This nanocarrier could passively target the tumor site through the EPR effect and achieve multimodal imaging (fluorescence, photoacoustic, photothermal and magnetic resonance imaging) of the tumor. Synergistic cancer photoimmunotherapy was achieved via simultaneous photodynamic and photothermal methods with 808 nm laser irradiation. ICG-CpG@MOF achieved the GSH-controlled release of immunoadjuvant into the tumor microenvironment. Furthermore, the released tumor-associated antigen along with CpG could induce the transformation of tumor cells from cold to hot by activating the immune system, which significantly enhanced tumor cytotoxicity and achieved high cure rates with minimal side-effects. This strategy utilizing multimodal imaging and synergistic cancer photoimmunotherapy provides a promising approach for the diagnosis and treatment of cancer.

show abstract

Section: Introductionsmentioning

confidence: 99%

Reversing cold tumors to hot: An immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy

Fan

Liu

Xue

et al. 2021

Bioactive Materials

135

View full text Add to dashboard Cite

show abstract

“…Fluorescence imaging and magnetic resonance (MR) can be used to observe that OVA@Mn‐DAP effectively transmits DAP and OVA to the lymph nodes. Experiments showed that this OVA@Mn‐DAP nanoparticle could prevent the growth of B16‐OVA melanoma, and the combination of ICB therapy and OVA@Mn–DAP nanovaccine had more substantial therapeutic effect [92] …”

Section: Combination Of Nanotechnology‐based Immune Checkpoint Blockimentioning

confidence: 98%

“…Experiments showed that this OVA@Mn-DAP nanoparticle could prevent the growth of B16-OVA melanoma, and the combination of ICB therapy and OVA@Mn-DAP nanovaccine had more substantial therapeutic effect. [92] In another study, João reported on the treatment of mannose anti-tumor nano-vaccine in combination with ibrutinib and OX40/PD-1 immune checkpoint. Mannose-based nanovaccine can target dendritic cells, myeloid suppressor ibrutinib can promote CD4 + T cell proliferation and DC maturation, thereby increasing the secretion of related cytokines, and anti-aPD-1 and anti-OX40 antibody had synergistic ICB therapeutic effect.…”

Section: Nano Vaccinementioning

confidence: 99%

Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints

Sun

et al. 2020

ChemistrySelect

View full text Add to dashboard Cite

Tumor immunotherapy has received worldwide attention in cancer treatment owing to its apparent advantages, such as strong specificity and long curative effect. Among them, significant progress has been made on the immune checkpoint therapy in recent years. FDA approved PD‐L1/PD‐1 and CTLA‐4 immune checkpoint inhibitors have been broadly used in a variety of malignant tumors. However, because of the low response rate of immune checkpoint drugs, its clinical application has been greatly hindered. With the prominence of nanotechnology in bio‐medicine, the application of nanotechnology in immune checkpoints has also gained more and more attention. The combination of radiotherapy, chemotherapy, phototherapy, magnetic therapy and other methods in nanotechnology makes an excellent promoting effect in the treatment of immune checkpoint drugs. This article reviews the recent breakthroughs of nanotechnology in immune checkpoint blocking therapy, mainly focusing on the significant advantages of the combination of nanotechnology‐based immune checkpoint blocking therapy with other treatment methods. In addition, we also discussed the challenges in this area and pointed out some potential directions for future development.

show abstract

“…13,14 The increasing interest in nanotechnology for cancer is due to its unique and attractive features, such as its utility for drug delivery, diagnosis, imaging, and synthetic vaccine development, as well as the inherent therapeutic properties of some nanomaterials. [15][16][17] To precisely control the release of drug at the tumor site and to meet requirements for increased anti-tumor effect and reduced damage to normal tissues, research has made great contributions in the area of stimuli-responsive release of materials (for example, pH, redox state, and enzymes). [18][19][20] Based on the characteristic acidity of the tumor microenvironment, Li et al 21 developed pHresponsive nanoparticles that improved the anti-tumor effect of paclitaxel on drug-resistant and metastatic breast cancer.…”

Section: Introductionmentioning

confidence: 99%

<p>Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer</p>

Deng¹,

Zhu²,

Yu³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Although single-drug chemotherapy is still an effective treatment for esophageal cancer, its long-term application is limited by severe side-effects, poor bioavailability, and drug-resistance. Increasing attention has been paid to nanomedicines because of their good biological safety, targeting capabilities, and high-efficiency loading of multiple drugs. Herein, we have developed a novel T7 peptide-modified pH-responsive targeting nanosystem co-loaded with docetaxel and curcumin for the treatment of esophageal cancer. Methods: Firstly, CM-β-CD-PEI-PEG-T7/DTX/CUR (T7-NP-DC) was synthesized by the double emulsion (W/O/W) method. The targeting capacity of the nanocarrier was then investigated by in vitro and in vivo assays using targeted (T7-NP) and non-targeted nanoparticles (NP). Furthermore, the anti-tumor efficacy of T7-NP-DC was studied using esophageal cancer cells (KYSE150 and KYSE510) and a KYSE150 xenograft tumor model. Results: T7-NP-DC was synthesized successfully and its diameter was determined to be about 100 nm by transmission electron microscopy and dynamic light scattering. T7-NP-DC with docetaxel and curcumin loading of 10% and 6.1%, respectively, had good colloidal stability and exhibited pH-responsive drug release. Good biosafety was observed, even when the concentration was as high as 800 μg/mL. Significant enhancement of T7-NP uptake was observed 6 hours after intravenous injection compared with NP. In addition, the therapeutic efficacy of T7-NP-DC was better than NP-DC and docetaxel in terms of growth suppression in the KYSE150 esophageal cancer model. Conclusion: The findings demonstrated that T7-NP-DC is a promising, non-toxic, and controllable nanoparticle that is capable of simultaneous delivery of the chemotherapy drug, docetaxel, and the Chinese Medicine, curcumin, for treatment of esophageal cancer. This novel T7-modified targeting nanosystem releases loaded drugs when exposed to the acidic microenvironment of the tumor and exerts a synergistic anti-tumor effect. The data indicate that the nanomaterials can safely exert synergistic anti-tumor effects and provide an excellent therapeutic platform for combination therapy of esophageal cancer.

show abstract

Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy

Cited by 96 publications

References 42 publications

Reversing cold tumors to hot: An immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy

Reversing cold tumors to hot: An immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy

Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints

<p>Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer</p>

Contact Info

Product

Resources

About